Celcuity Inc. (CELC) Stock Forecast Oct. 30, 2026
Analysis updated on Oct. 30, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Celcuity Inc. (CELC) stock forecast summary
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
Celcuity Inc. is a mid-cap company with a market capitalization of $3.38B. It ranks number 11 by market capitalization among the 26 Services-Medical Laboratories issuers in our coverage with a current forecast.
For CELC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 11.0%, measured on 357 forecast dates between 2022-08-12 and 2026-07-31 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 3.0%, measured on 400 forecast dates between 2022-08-12 and 2026-09-30. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
CELC price chart and AI forecast
How CELC ranks among 4891 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Celcuity Inc. (CELC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | CELC | Rank |
|---|---|---|
| Market Cap | $3.38B | 11/26 |
| EPS | $-4.19 | – |
| FCF/Share | $-3.93 | – |
Profitability & Margins
| Metric | CELC | Rank |
|---|---|---|
| ROA | -27.4% | 13/18 |
| ROIC | -28.1% | 16/21 |
Financial Health
| Metric | CELC | Rank |
|---|---|---|
| Current Ratio | 8.93x | 5/23 |
| Interest Coverage | -18.9x | 12/20 |
| Working Capital | $689M | 7/23 |
Cash Flow
| Metric | CELC | Rank |
|---|---|---|
| Operating Cash Flow | -$192M | 23/24 |
| Free Cash Flow | -$192M | 15/17 |
| Capital Spending | -$450K | 2/17 |
Income Statement
| Metric | CELC | Rank |
|---|---|---|
| Operating Income | -$209M | 20/23 |
| Net Income | -$226M | 16/18 |
| R&D Expense | $137M | 5/18 |
Dividend & Shareholder Information
| Metric | CELC | Rank |
|---|---|---|
| Shares Outstanding | 49M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $776M | |
| Cash & Short-term Investments | $182M | |
| Total Liabilities | $841M | |
| Short-term Debt | $79M |
CELC quarterly financials and insider trading
Celcuity Inc. (CELC) industry peers
Companies classified under the same SEC industry code as Celcuity Inc. (Services-Medical Laboratories): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CELC Celcuity Inc. | $3.38B | |
| NTRA Natera, Inc. | $54.62B | |
| LH Labcorp Holdings Inc. | $28.84B | |
| DGX Quest Diagnostics Inc | $27.18B | |
| GH Guardant Health, Inc. | $23.48B | |
| CAI Caris Life Sciences, Inc. | $9.70B | |
| GRAL Grail, Inc. | $6.23B | |
| RDNT Radnet, Inc. | $5.78B | |
| BLLN Billiontoone, Inc. | $5.21B | |
| CDNA Caredx, Inc. | $4.52B | |
| VCYT Veracyte, Inc. | $3.94B | |
| FTRE Fortrea Holdings Inc. | $2.02B | |
| PSNL Personalis, Inc. | $1.68B | |
| FRNM Freenome, Inc. | $1.23B | |
| CSTL Castle Biosciences Inc | $1.07B | |
| LMRI Lumexa Imaging Holdings, Inc. | $1.07B | |
| FLGT Fulgent Genetics, Inc. | $533M | |
| BDSX Biodesix Inc | $222M | |
| XGN Exagen Inc. | $203M | |
| BNR Burning Rock Biotech Ltd | $117M | |
| SERA Sera Prognostics, Inc. | $78M | |
| MDXH Mdxhealth Sa | $18M | |
| AMS American Shared Hospital Services | $8M | |
| ACON Aclarion, Inc. | $5M | |
| ADVB Advanced Biomed Inc. | $3M | |
| BGLC Bionexus Gene Lab Corp | $3M | |
| RNLXY Renalytix Plc | N/A |
Where CELC sits on the market map
Celcuity Inc. (CELC) stock news
Loading...
Celcuity Inc. (CELC) stock forecast FAQ
What is the Celcuity Inc. (CELC) stock forecast?
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
How accurate are Celcuity Inc. stock predictions?
For CELC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 11.0%, measured on 357 forecast dates between 2022-08-12 and 2026-07-31 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 3.0%, measured on 400 forecast dates between 2022-08-12 and 2026-09-30. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Celcuity Inc. forecasts updated?
Celcuity Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 30, 2026.
Which companies are Celcuity Inc.'s industry peers?
27 issuers in our coverage, CELC included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Labcorp Holdings Inc. (LH), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Grail, Inc. (GRAL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.